Acquisitions Management Operations Branch, NIAID, 6003 Executive Blvd, Solar Building, Room 1A25, Contracts Section, Bethesda MD 20892-7605

99 -- MANUFACTURING YEAST-PRODUCED MALARIA VACCINES SOL NIAID-DIR-95-57 DUE 071795 POC Karin E. Eddy, Contracting Officer (301) 496-3878 Rebecca A. Guenthner, Contracting Officer (301) 402-2284. The Laboratory of Malaria Research of the National Institute of Allergy and Infectious Diseases intends to contract with Immunex Corporation for the manufacture of materials for advanced malaria vaccine development. Immunex Corporation provided NIAID with a proprietary yeast expression system for preliminary vaccine development purposes. The system was modified to express abundant amounts of biologically active Pfs25. To secure high quality clinical grade (Good Manufacturing Practices-grade) material, the modified proprietary expression system was returned to Immunex Corporation for a series of pilot scale fermentations and purification. At this stage in development the clinical grade material will be required over the next three to five years. Because the initial clinical studies will be performed with the material manufactured at Immunex it is imperative for the sake of consistency and so as not to introduce any unknown variables that further clinical grade material also be manufactured by Immunex. See Numbered Note 22. No telephone requests for RFPs will be accepted. (0123)

Loren Data Corp. http://www.ld.com (SYN# 0492 19950504\99-0002.SOL)